Frequently Asked Questions
The market is segmented based on , By Type (Schistosoma Mansoni, Schistosoma Japonicum, Others), Drugs (Praziquantel, Metrifonate, Oxamniquine, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Schistosomiasis Diseases Market size was valued at USD 70.00 USD Million in 2021.
The Global Schistosomiasis Diseases Market is projected to grow at a CAGR of 4% during the forecast period of 2022 to 2029.
The major players operating in the market include Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GSK plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Abbvie , AstraZeneca, Johnson & Johnson Private Limited, Cipla , Abbott, Bausch Health Companies , Lupin, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC., Seagen , ONO Pharmaceutical Co., .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
